Somewhat Positive Press Coverage Somewhat Unlikely to Affect CoLucid Pharmaceuticals (NASDAQ:CLCD) Stock Price

News stories about CoLucid Pharmaceuticals (NASDAQ:CLCD) have trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive media coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. CoLucid Pharmaceuticals earned a coverage optimism score of 0.15 on Accern’s scale. Accern also gave media headlines about the biopharmaceutical company an impact score of 45.6250870984296 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.

ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Affect CoLucid Pharmaceuticals (NASDAQ:CLCD) Stock Price” was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another site, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this news story can be viewed at https://www.com-unik.info/2017/08/19/somewhat-positive-media-coverage-somewhat-unlikely-to-affect-colucid-pharmaceuticals-nasdaqclcd-stock-price-updated-updated-updated.html.

CoLucid Pharmaceuticals Company Profile

CoLucid Pharmaceuticals, Inc is a Phase III clinical-stage biopharmaceutical company. The Company is engaged in developing a small molecule for the acute treatment of migraine headaches. Its product candidates address the needs of migraine patients, including those with cardiovascular risk factors or stable cardiovascular disease and those dissatisfied with existing therapies.

Insider Buying and Selling by Quarter for CoLucid Pharmaceuticals (NASDAQ:CLCD)

What are top analysts saying about CoLucid Pharmaceuticals Inc? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for CoLucid Pharmaceuticals Inc and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit